Vilon
Also known as: Vilon peptide, KE, Lys-Glu, Lysylglutamic acid
5 notable studies · 4 references
TLDR
Vilon is the synthetic dipeptide Lys-Glu (KE), with a relatively broad preclinical literature involving thymocyte proliferation, thymic tissue, apoptosis, neuroendocrine signaling, experimental tumors, and mouse aging/lifespan, plus direct experiments in human-derived immune cells, but robust independently replicated human clinical evidence for immune restoration, anti-aging, cancer prevention, or longevity has not been established.
Research Supports
- Studied for thymocyte proliferation and thymic-tissue-specific activity
- Investigated for effects on radiation-induced lymphocyte apoptosis
- Examined in mouse aging/lifespan and spontaneous-tumor studies
- Studied for neuroendocrine and reproductive aging effects in male rats
- Investigated for effects on intestinal enzyme activity in aged rats
Observations Reported in Research
- Produced the strongest comitogenic effect on thymocyte proliferation among three compared peptides, with increased sphingomyelinase activity (Khavinson et al., 2002)
- Increased lifespan and reduced spontaneous neoplasms in long-term-treated female CBA mice (Khavinson & Anisimov, 2000)
- Reduced bladder-tumor incidence to 56% vs 75.5% in controls in a chemically induced rat model
- Increased expression of nucleolar-organizer-region proteins in human thymocytes and thymic epithelial cells (Raikhlin et al., 2004)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic dipeptide; short peptide bioregulator; experimental thymic/immunoregulatory peptide
Vilon is refreshingly straightforward chemically: Lys-Glu or KE. Unlike Testagen, its identity is directly established in numerous indexed publications. PubMed explicitly identifies Vilon as Lys-Glu/lysylglutamic acid. It has been investigated in thymocytes, thymic epithelium, spleen lymphocytes, aging mice, tumor models, intestinal tissue, oxidative-stress experiments, neuroendocrine and reproductive aging in rats, and human-derived lymphocytes. That's a surprisingly broad experimental record for a molecule containing only two amino acids. Broad preclinical evidence does not equal established human clinical efficacy. The literature is old, geographically concentrated and overwhelmingly connected to the originating Khavinson research program.
What Is Vilon?
Vilon is the synthetic dipeptide L-Lys-L-Glu (KE). It was developed within research on thymic peptide bioregulators and is most strongly associated with thymus biology, immune-cell regulation, aging, and cell proliferation/apoptosis. Its thymic association has direct experimental support. In organotypic cultures, Vilon stimulated thymus explant growth, while Cortagen, Epitalon and Livagen preferentially stimulated their corresponding tissue cultures. That gives Vilon a substantially better tissue-specificity argument than Testagen.
What Are Researchers Studying?
Thymocyte proliferation
A 2002 experiment examined Vilon, Epitalon and Cortagen in mouse thymocytes. Vilon produced the strongest comitogenic effect on thymocyte proliferation, altered the effect of interleukin-1β and increased sphingomyelinase activity more strongly than the comparator peptides. This provides direct evidence for immune-cell activity and a plausible signaling pathway.
Thymic tissue
In organotypic cultures, Vilon stimulated development of rat thymus explants while other short peptides showed different tissue associations. A separate human-cell experiment found that Vilon stimulated expression of argyrophilic proteins in nucleolar organizer regions of human thymocytes and thymic epithelial cells, consistent with increased ribosome formation/protein-synthesis activity. That is unusually direct tissue evidence for this peptide family.
Apoptosis
Vilon has been investigated in radiation-associated lymphocyte apoptosis. In rat spleen lymphocytes, Vilon inhibited irradiation-induced programmed cell death more strongly than Epitalon in the reported experiment. This does not mean inhibition of apoptosis is universally beneficial. Apoptosis is also essential for removing damaged cells, immune regulation, and tumor suppression. Context matters enormously.
Aging and lifespan
Vilon has one of the more striking animal-aging studies in this family. Long-term administration to female CBA mice was reported to increase physical activity, increase endurance, lower body temperature, increase lifespan, and reduce spontaneous neoplasms. The investigators reported no unfavorable developmental effects during chronic exposure. This is genuine lifespan research. But it remains one research lineage + one mouse strain ≠ demonstrated human longevity therapy.
Tumor development
Vilon has been investigated in several experimental tumor contexts. One mouse study reported reduced spontaneous tumor development alongside increased lifespan. In a chemically induced rat bladder-cancer model, tumors occurred in 56% of Vilon-treated rats versus 75.5% of controls, with fewer preneoplastic/early neoplastic changes reported. This is interesting preclinical oncology research. It absolutely does not establish Vilon as a cancer treatment or cancer-prevention drug in humans.
Oxidative stress
Vilon produced compartment-specific effects on reactive oxygen species in Drosophila melanogaster. It inhibited mitochondrial ROS generation while increasing cytosolic ROS generation, with effects differing by sex and age. That's more nuanced than simply calling Vilon an “antioxidant.” In fact, the experiment shows exactly why that label would be misleading.
Neuroendocrine and reproductive aging
Vilon was studied in old male rats and reportedly increased sexual activity while changing LH, prolactin, ACTH, and hypothalamic neurotransmitter levels. The authors particularly noted a decrease in elevated prolactin. This is legitimate reproductive-aging research—but importantly this evidence belongs to Vilon, not Testagen. That distinction is especially valuable with these two profiles side by side.
Intestinal aging
Oral Vilon given to old Wistar rats for one month increased activity of membrane enzymes including maltase and alkaline phosphatase in the small-intestinal epithelial layer and increased glycyl-L-leucine dipeptidase activity in deeper intestinal layers. This demonstrates that Vilon's experimental effects aren't limited to the thymus.
How Does It Work?
There probably isn't one mechanism. The best-supported experimental pathway involves Vilon / Lys-Glu → thymocyte-cell signaling → increased sphingomyelinase activity → altered sphingomyelin signaling → changes in proliferation/immune-cell activity. Other experiments suggest effects involving ribosomal-gene activity, chromatin organization, protein synthesis, apoptosis, neuroendocrine signaling, and oxidative stress. Cultured lymphocytes from elderly people exposed to Vilon showed deheterochromatinization and activation of chromatin-associated processes, although Vilon differed from Epitalon and Livagen in some pericentromeric effects. No single conventional Vilon receptor has been established.
What Does the Research Show?
Human research
Not robustly established as modern clinical evidence. A human clinical evidence badge would not be appropriate based on the verified material. Human-derived cells: YES. Direct experiments include human thymocytes, human thymic epithelial cells, and cultured lymphocytes from older adults. Human clinical evidence: VERY LOW / NOT ESTABLISHED. Human cellular evidence: MODERATE.
Animal research
MODERATE–HIGH relative to the rest of the Khavinson family. Vilon has direct studies involving mice, rats, Drosophila, aging, lifespan, tumor development, reproductive/neuroendocrine biology, intestinal physiology, and immune function. The primary weakness is independence, not quantity.
In-vitro research
MODERATE. The direct mechanistic literature includes thymocytes, thymic epithelium, lymphocytes, and organotypic thymus cultures.
Notable Studies
Effects of Short Peptides on Thymocyte Blast Transformation and Signal Transduction Along the Sphingomyelin Pathway
in-vitroVilon, Epitalon and Cortagen were compared in mouse thymocytes. Vilon produced the strongest stimulation of thymocyte proliferation and the greatest stimulation of sphingomyelinase activity among the three peptides.
Limitations: Isolated mouse-cell experiment; immune-cell proliferation and enzyme activity don't establish improved immunity or clinical benefit.
View publication →Effect of Vilon on Biological Age and Lifespan in Mice
animalLong-term subcutaneous Vilon exposure in female CBA mice was associated with increased physical activity/endurance, lower body temperature, increased lifespan and fewer spontaneous neoplasms.
Limitations: Single mouse strain, originating research network, uncertain generalizability and no demonstration of human longevity effects.
View publication →A Synthetic Dipeptide Vilon (L-Lys-L-Glu) Inhibits Growth of Spontaneous Tumors and Increases Life Span of Mice
animalResearchers studied long-term Vilon exposure in mice and reported reduced spontaneous tumor development alongside increased lifespan.
Limitations: Animal study from the originating research group; doesn't establish cancer prevention or longevity efficacy in humans.
View publication →Expression of Argyrophilic Proteins in the Nucleolar Organizer Regions of Human Thymocytes and Thymic Epitheliocytes Under Conditions of Coculturing with Vilon and Epithalon Peptides
in-vitroVilon increased expression of nucleolar-organizer-region proteins in human thymocytes and thymic epithelial cells, interpreted as increased ribosome formation and protein-synthesis activity.
Limitations: Human cells in culture rather than administration to people; molecular/cellular endpoints don't establish improved immune function.
View publication →Effect of Vilon on Neuroendocrine Status and Sexual Function of Old Male Rats
animalVilon increased sexual activity in old male rats and altered LH, prolactin, ACTH and hypothalamic neurotransmitter measures; decreased prolactin was highlighted by the investigators.
Limitations: Aging-rat model; hormonal changes and sexual behavior do not establish testosterone restoration, fertility enhancement or clinical effects in humans.
View publication →What We Still Don't Know
Human pharmacokinetics; Human oral bioavailability; Plasma half-life; Optimal experimental exposure; Whether meaningful intact KE reaches the thymus in humans; Primary molecular target; Whether immune-cell effects improve actual infection resistance; Whether it improves vaccine responses; Whether it alters clinically meaningful immunosenescence; Whether its mouse lifespan effect independently replicates; Whether it affects human lifespan or healthspan; Whether tumor findings translate to humans; Long-term human safety; Whether chronic apoptosis modulation could produce undesirable effects; Independent replication outside the originating research network.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Vilon research with you.
Get the Aminodex Vilon Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Khavinson VKh, Rybakina EG, Malinin VV, et al. Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway. Bull Exp Biol Med. 2002.
- Khavinson VK, Anisimov VN, Zavarzina NY, et al. Effect of Vilon on biological age and lifespan in mice. Bull Exp Biol Med. 2000.
- Khavinson VKh, Anisimov VN. A synthetic dipeptide Vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000.
- Raikhlin NT, Bukaeva IA, Smirnova EA, et al. Expression of argyrophilic proteins in the nucleolar organizer regions of human thymocytes and thymic epitheliocytes under conditions of coculturing with Vilon and Epithalon peptides. Bull Exp Biol Med. 2004.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.